Clinical Trial: Effect of Anti-osteoporotic Medications on Nonalcoholic Fatty Liver Disease
Study Status: COMPLETED
Recruit Status: COMPLETED
Condition:
Nonalcoholic Fatty Liver
Osteoporosis, Postmenopausal
Study Type: INTERVENTIONAL
Official Title: Effect of Anti-osteoporotic Medications on Hepatic Steatosis and Fibrosis of Women With Postmenopausal Osteoporosis and Nonalcoholic Fatty Liver Disease
Brief Summary:
Nonalcoholic fatty liver disease (NAFLD) is a chronic, metabolic liver disease that is closely related to obesity, type 2 diabetes mellitus (T2DM) and metabolic syndrome (MetS) in a bidirectional mode. NAFLD affects approximately 25% of the worldwide population. NAFLD refers to a phenotypic spectrum, including steatosis, inflammation and fibrosis, which can lead to cirrhosis and hepatocellular carcinoma in a minority of patients. However, despite its high prevalence, morbidity and mortality, as well as the…
Read more